ASFX (ASFX) Stock Price & Analysis
ASFX (ASFX) rose 0.00% to USD 0 as of June 10, 2026 at 05:09 UTC, according to Nexqual real-time market data.
ASFX last closed at USD 0; the session ranged USD 0–0 on volume of 70 shares. Market capitalization is $902, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 05:09 UTC.
Key Statistics (as of June 10, 2026 at 05:09 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 70 shares |
| Market Cap | $902 |
| Exchange | PNK |
Technical Analysis (ASFX)
Nexqual's technical model rates ASFX "BUY" based on 1 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 05:09 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Above (USD 0) |
Analyst Ratings (ASFX)
Wall Street analysts rate ASFX "None", per Nexqual as of June 10, 2026 at 05:09 UTC.
| Consensus Rating | None |
|---|
Earnings (ASFX)
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Financials & Fundamentals (ASFX)
| Total Revenue | $1.05M |
|---|---|
| Revenue Growth (YoY) | +65.40% |
| Gross Margin | +21.51% |
| Operating Margin | -128.09% |
| Profit Margin | +0.00% |
| Current Ratio | 0.09 |
| Total Cash | $19,618 |
| Total Debt | $5.67M |
| Free Cash Flow | $-1.56M |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Financial Health Score (ASFX)
Nexqual rates ASFX's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:09 UTC.
| Growth | Strong — Revenue +65% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $20K cash vs $6M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ASFX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 30.09M |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HTDS | HARD TO TREAT DISEASES INC | USD 0 | ▲ 0% |
| IGNT | INGEN TECHNOLOGIES INC | USD 0 | ▲ 0% |
| LLBO | Lifeline BioTechnologies, Inc. | USD 0 | ▲ 40% |
| PDMI | Paradigm Medical Industries, In | USD 0 | ▲ 0% |
| BIEL | BioElectronics Corp. | USD 0 | ▼ 25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:09 UTC. This page is informational and not investment advice.